Overview

* Regeneron Q3 2025 revenue grows 1% to $3.75 bln, beating analyst expectations

* Adjusted EPS for Q3 2025 beats consensus, driven by strong product sales

* Company reports strong sales growth for Dupixent and EYLEA HD

Outlook

* Regeneron updates 2025 R&D expense guidance to $5.68-$5.75 bln

* Company revises 2025 SG&A expense guidance to $2.775-$2.845 bln

* Regeneron expects 2025 GAAP effective tax rate of approximately 14%

Result Drivers

* DUPIXENT SALES - Dupixent global net sales increased 27%, boosting collaboration revenue with Sanofi

* EYLEA HD DEMAND - EYLEA HD U.S. net sales rose 10% due to higher demand, despite competitive pressures

* FDA APPROVALS - FDA approvals for Libtayo and other products boosted Regeneron's late-stage portfolio

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $3.75 $3.58

Revenue bln bln (20

Analysts

)

Q3 Beat $11.83 $9.58

Adjusted (21

EPS Analysts

)

Q3 EPS $13.62

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Regeneron Pharmaceuticals Inc ( REGN ) is $748.16, about 21.8% above its October 27 closing price of $585.31

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)